For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Ranibizumab | ranibizumab: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME. | None | None | 0 | 5 | 5 | 5 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Floaters | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Eye Pain | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Blurry Vision | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Uveitis in fellow eye | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Anterior uveitis | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Dry Eye | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Cataract | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Glaucoma | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Ocular pruritis | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |